Increased Serum Levels of IL-17 A and IL-22 Are Associated with Autism Spectrum Disorder

January 29, 2024

New Study Suggests IL-22 Could Be a Future Effective Target for ASD Treatment

A recent research article has explored the role of immune system dysregulation, particularly focusing on interleukin (IL)-17 A and interleukin (IL)-22 in Autism Spectrum Disorder (ASD). IL-17 and IL-22 are cytokines that play critical roles in host defense against microbes and the development of chronic inflammatory diseases. The current study found that serum levels of both IL-17 A and IL-22 are significantly higher in ASD patients than controls. Furthermore, the authors discovered that IL-22 is positively correlated with ASD severity and believe that focusing on IL-22 could have potential as an effective therapeutic target in treating the disorder. This research also recognized the potential role of these cytokines in autoimmune neuroinflammatory illnesses, central nervous system disorders and their involvement in regulating the Th17/T-regulatory cell ratio. Additionally, this study explored the association between immune-related disorders, family history of autoimmune diseases, and ASD. Ultimately, this research provides insights into the intricate relationship between immune system markers and ASD, emphasizing the need for further investigations to understand the underlying pathophysiological mechanisms and potential implications for diagnosis and treatment.

Original Study

Show Buttons
Hide Buttons